Navigation Links
Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
Date:8/30/2012

INDIANAPOLIS, Aug. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Michael J. Harrington will be promoted to senior vice president and general counsel effective Jan. 1, 2013.  Harrington will replace Robert A. Armitage who will retire at the end of the year.

Harrington, vice president and deputy general counsel, is currently responsible for the legal function across Lilly's five business units.  In his new role, he will report to John Lechleiter, Ph.D., chairman, president, and CEO, and will serve on the company's executive committee.

Commenting on Armitage's career, Lechleiter stated, "Bob Armitage has left a lasting impact on Lilly and the biopharmaceutical industry with his exceptional contributions, particularly in the field of intellectual property. He also has provided keen insight and extraordinary leadership across a range of business issues affecting our company. It's been an absolute privilege to work with him."

Armitage played a major role in the successful efforts leading to the passage last year of the America Invents Act, which made the most sweeping changes to U.S. patent law in 175 years. In 2011, he became one of a select group of only 47 individuals who have been inducted in the Intellectual Property Hall of Fame, which includes U.S. presidents Jefferson and Madison. Armitage joined Lilly in 1999 as vice president and general patent counsel, Lilly Research Laboratories.  For the last decade, he has led Lilly's global legal organization as the company's general counsel.

Harrington is a graduate of the Columbia University School of Law. He joined the company in 1991 and has served in a number of business and legal positions with Lilly, including managing director of Eli Lilly New Zealand, general counsel for Lilly's Asia-Pacific operations and deputy general counsel with responsibility for all litigation, manufacturing, environmental and human resources matters.

"We are very fortunate to have Mike Harrington to take Bob's place. Mike is well-prepared for his new assignment. He has been instrumental in handling many of the key legal challenges we have faced in the last few years. His extensive global experience, deep knowledge of the business, and his passion for Lilly's mission will serve our company well," said Lechleiter.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information ─ for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.  C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Photo: http://photos.prnewswire.com/prnh/20120830/DE64980-a)

(Photo: http://photos.prnewswire.com/prnh/20120830/DE64980-b)

 


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
2. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
3. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
4. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
5. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
6. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
7. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
8. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
9. Lilly Diabetes Announces Once Upon A Time Contest Winner
10. Lilly Statement on Affordable Care Act Ruling by Supreme Court
11. Lilly Statement on PDUFA Vote by Senate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... December 8, 2016 According to a new market ... Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart ... MarketsandMarkets, the global market, in terms of value, is projected to reach ... CAGR of 18.0% during the forecast period. ... ...
(Date:12/8/2016)... 2016  Haemonetics Corporation (NYSE: HAE ) has ... an innovative software suite designed to help customers drive efficiency ... of NextGen DMS 4 improves core features and introduces innovations ... liter of plasma collected, enhancing quality and regulatory compliance and ... ...
(Date:12/8/2016)... , and SAN DIEGO , Dec. 8, ... and solutions with cutting edge next-generation sequencing and bioinformatics expertise; ... company; and the Genome Institute of Singapore ... a new joint venture between Novogene and AITbiotech – will ... Singapore .   The new ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare ... Act. Dr. Botelho advocates for the mass media launching of story movements to ... opportunities to share their unfortunate experiences; such a movement can generate the network ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter ... communities in and around the greater Phoenix metropolitan region, is announcing a charity ... The mission of the Homeless Youth Connection is to promote community awareness of ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... and deep lines by smoothing and tightening the skin of the face to ... to address facial aging with very little downtime, Silhouette Instalift is a novel, ...
(Date:12/7/2016)... Ca (PRWEB) , ... December 07, 2016 , ... It ... that funding is with useful, properly analyzed data. The team at Beckman Coulter has ... address the 'need for speed' and the need to operate in a GLP (Good ...
Breaking Medicine News(10 mins):